•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Kairos Pharma, Ltd. (NYSE American: KAPA) announced it will participate in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18 and 19, 2026.
The company is scheduled to present on Monday, May 18, 2026 at 1:00 PM PDT. John Yu, CEO, will present on behalf of Kairos Pharma.
Dr. John Yu, CEO and Chairman of Kairos Pharma, will provide an update on the company’s clinical program and partnering activities.
The two-day event will feature micro and small-cap companies across all sectors, with presentations in half-hour increments and private meetings with investors.
Kairos Pharma, Ltd., based in Los Angeles, California, focuses on oncology therapeutics using structural biology to address drug resistance and immune suppression in cancer. The company’s lead candidate, ENV105, is an antibody targeting CD105, a protein described as a key driver of resistance to various cancer treatments.
According to the company, elevation of CD105 in response to standard therapy is associated with resistance and disease relapse. ENV105 is intended to reverse drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types.
LD Micro is a wholly owned subsidiary of Freedom US Markets. Founded in 2006, it is described as an independent resource in the micro-cap space, providing investor-driven conferences and curated company exposure.
For registration, contact: registration@ldmicro.com.
Source: LD Micro.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
